BioSig Technologies, Inc. Appoints David J. Drachman as Chief Executive Officer & Chairman
LOS ANGELES, Sept. 18, 2013 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (BioSig), a medical device company developing innovative technology solutions for the electrophysiology market, announced today the appointment of David J. Drachman as President, Chief Executive Officer and Chairman of the Board, effective immediately. Mr. Drachman transitions leadership from co-founder and Board member, Kenneth L. Londoner.
David J. Drachman brings to BioSig 27 years of leadership in the cardiovascular medical device industry. Most recently, he served as President, Chief Executive Officer and Director of AtriCure Inc. (Nasdaq:ATRC), a leader in the surgical treatment of atrial fibrillation (AF). During his tenure, the AtriCure team expanded their product portfolio from one to six unique platforms and had grown from a startup to a market leader with distribution channels in more than 30 countries. AtriCure became the first and remains the only company to receive FDA, PMA approval for the surgical treatment of AF. David also held key Executive positions at Biosense Webster and led the initial commercialization process. Today, Biosense Webster, a Johnson & Johnson company, is a worldwide leader in the electrophysiology market. Additionally, David served as acting CEO, Worldwide President & Director of Impulse Dynamics, and had distinguished positions at Ventritex and Boston Scientific.
Kenneth L. Londoner, co-founder, departing Chairman and Chief Executive Officer of BioSig Technologies, Inc., commented, "Today marks a new era in the growth of our Company. Dave is one of the preeminent leaders of our industry - BioSig and its stakeholders will enormously benefit from his deep domain expertise and achievements. We are delighted to welcome Dave as a leader to the team and look forward to many years of growth and success."
David J. Drachman said, "It is a privilege to join the BioSig team - we share the same passion for innovation and execution. I'm confident that BioSig's novel technologies will provide important solutions for electrophysiologists to ultimately improve patient outcomes, and deliver market-leading performance."
About BioSig Technologies, Inc.
BioSig Technologies, Inc. is a medical device company developing clinical solutions for the diagnosis and treatment of arrhythmia. BioSig's PURE EP™ System is designed to assist electrophysiologists during the termination of an irregular heartbeat by catheter ablation. The PURE EP™ System empowers electrophysiologists to make crucial clinical decisions in real-time by providing information currently not obtainable from any other equipment in the EP lab.
CONTACT: Lora Mikolaitis
Director of Operations
info@biosigtech.com
Released September 18, 2013
